[1]吴忠璟,陈亚凤,高芳虹.糖尿病肾病患者血清miR-135b水平检测与疾病预后的相关性研究[J].现代检验医学杂志,2018,33(03):88-91.[doi:10.3969/j.issn.1671-7414.2018.03.022]
　WU Zhong-jing,CHEN Ya-feng,GAO Fang-hong.Correlation between Serum miR-135b Level and Prognosis in Patients with Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2018,33(03):88-91.[doi:10.3969/j.issn.1671-7414.2018.03.022]
点击复制

糖尿病肾病患者血清miR-135b水平检测与疾病预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年03期
页码:
88-91
栏目:
论著
出版日期:
2018-07-17

文章信息/Info

Title:
Correlation between Serum miR-135b Level and Prognosis in Patients with Diabetic Nephropathy
文章编号:
1671-7414(2018)03-088-04
作者:
吴忠璟; 陈亚凤; 高芳虹
海口市妇幼保健院检验科,海口 570102
Author(s):
WU Zhong-jing; CHEN Ya-feng; GAO Fang-hong
Department of Clinical Laboratory, Haikou Maternal and Child Health Care Hospital,Haikou 570102,China
关键词:
糖尿病肾病;  微小核糖核酸-135b(miR-135b);  预后评估
分类号:
R587.2; R392.11
DOI:
10.3969/j.issn.1671-7414.2018.03.022
文献标志码:
A
摘要:
目的 探讨血清miR-135b水平与糖尿病肾病(DN)患者预后的关系。方法 采用实时荧光定量聚合酶链反应(RT-PCR)检测158例DN患者(DN组)和60例健康体检者(对照组)血清miR-135b水平,分析miR-135b与DN患者不同临床指标的关系。采用肾小球分级、间质性纤维化和小管萎缩评分(IFTA)及间质炎症来评价肾脏损伤情况,并应用ROC曲线分析血清miR-135b水平预测DN患者发生终末期肾病(ESRD)的价值。结果 DN组血清miR-135b水平为3.94±0.75,明显高于对照组0.64±0.13,差异有统计学意义(t=9.317,P<0.01)。血清miR-135b水平与蛋白尿定量、Cr,BUN及eGFR水平相关(P<0.05)。DN患者血清miR-135b水平与肾小球分级、IFTA及间质炎症均有关,且随着肾脏病理损伤程度的增加,血清miR-135b水平明显升高(P<0.05)。终末期肾病(ESRD)患者血清miR-135b水平(5.39±1.26)明显高于非ESRD患者(3.46±0.68),差异有统计学意义(t=4.157,P=0.025)。ROC曲线显示,血清miR-135b水平预测DN患者发生ESRD的最佳截值取4.96时,其AUC[0.912(95%CI:0.850～0.973)]最大,敏感度(91.3%)和特异度(87.5%)较好。Spearman相关分析显示,DN患者血清miR-135b水平与蛋白尿定量、Cr,BUN,肾小球分级,IFTA及间质炎症呈正相关(r=0.504,0.396,0.438,0.475,0.351和0.559,均P<0.01),与eGFR呈负相关(r=-0.637,P<0.01)。结论 血清miR-135b水平在DN患者中明显上调,且与DN患者肾脏损伤及预后不良有关。
Abstract:
Abstract:Objective To investigate the relationship between the level of serum miR-135b and the prognosis of diabetic nephropathy(DN).Methods Real time fluorescence quantitative polymerase chain reaction(RT-PCR)was used to detect serum miR-135b level in 158 patientswith DN(group DN)and 60 healthy controls(control group).The relationship between miR-135b and different clinical indicators in patients with DN was analyzed.Renal injury was evaluated by glomerular grading,interstitial fibrosis and tubular atrophy score(IFTA)and interstitial inflammation.ROC curve was used toanalyze serum miR-135b level to predict the value of end-stage renal disease(ESRD)in DN patients.Results The level of serum miR-135b in DN group was significantly higher than that in the control group(3.94±0.75 vs 0.64±0.13,t=9.317,P<0.01).Serum miR-135b level were associated with proteinuria,Cr,BUN,and eGFR levels(P<0.05).Serum miR-135b level in elderly patients with DN was related to glomerular grading,IFTA and interstitial inflammation.With the increase of renal pathological damage,serum miR-135b level was significantly increased(P<0.05).The level of serum miR-135b(5.39±1.26 vs 3.46±0.68)in patients with end-stage renal disease(ESRD)was significantly higher than that of non ESRD patients(t=4.157,P=0.025).The ROC curve showed that the serum miR-135b level predicted the best cut-off value of ESRD in DN patients when it was 4.96,and its AUC [0.912(95%CI:0.850-0.973)] was the largest,and its sensitivity(91.3%)and specificity(87.5%)were the best.Spearman correlation analysis showed that theDN the level of serum miR-135b and proteinuria,Cr,BUN,glomerular classification,IFTA,interstitial inflammation were positively correlated(r=0.504,0.396,0.438,0.475,0.351 and 0.559,all P<0.01),and negatively correlated with eGFR(r=-0.637,P<0.01).Conclusion Serum miR-135b levels were significantly up-regulated in patients with DN,and are associated with renal injury and poor prognosis in DN patients.

参考文献/References:

[1] Huang YQ,Gou R,Diao YS,et al.Charlson comorbidity index helpspredict the risk of mortality for patients with type 2 diabetic nephropathy[J].J Zhejiang Univ Sci B,2014,15(1):58-66.
[2] Morikawa S,Ito H,Watanabe K.Diabetic nephropathy[J].Der Nephrologe,2012,53(10):1195-1206.
[3] Yao ZY,Chen WB,Shao SS,et al.Role of exosome-associated microRNA indiagnostic and therapeutic applications to metabolic disorders[J].J ZhejiangUniv Sci B,2018,19(3):183-198.
[4] Pratap P,Raza ST,Abbas S,et al.MicroRNA-associated carcinogenesis inlung carcinomas[J].J Cancer Res Ther,2018,14(2):249-254.
[5] 何 凤,周姗姗,关昌杰,等.微小RNA-135b调控Smad5在糖尿病肾病发病中的作用研究[J].新医学,2017,48(5):317-322. He F,Zhou SS,Guan CJ,et al.Effect of micro RNA-135b on the pathogenesis of diabetic nephropathy by regulating Smad5[J].New Medicine,2017,48(5):317-322.
[6] American Diabetes Association.Diagnosis and classification of diabetes mellitus[J].Diabetes Care,2012,35(Suppl 1):S64-71.
[7] Moridikia A,Mirzaei H,Sahebkar A,et al.MicroRNAs:Potential candidates for diagnosis and treatment of colorectal cancer[J].J Cell Physiol,2018,233(2):901-913.
[8] Hershkovitz-Rokah H,Geva P,Salmon-Divon M,et al.Network analysis ofmicroRNAs,genes and their regulation in diffuse and follicular B-cell lymphomas[J].Oncotarget,2018,9(8):7928-7941.
[9] Nezu Y,Hagiwara K,Yamamoto Y,et al.MiR-135b,a key regulator of malignancy,is linked to poor prognosis in human myxoid liposarcoma[J].Oncogene,2016,35(48):6177-6188.
[10] Hua K,Jin J,Zhao J,et al.MiR-135b,upregulated in breast cancer,promotes cell growth and disrupts the cell cycle by regulating LATS2[J].Int J Oncol,2016,48(5):1997-2006.
[11] Simpson K,Wonnacott A,Fraser DJ,et al.MicroRNAs in diabetic nephropathy:from biomarkers to therapy[J].Curr Diab Rep,2016,16(3):35.
[12] Nassirpour R,Raj D,Townsend R,et al.MicroRNA biomarkers in clinicalrenal disease:from diabetic nephropathy renal transplantation and beyond[J].Food Chem Toxicol,2016,98(Pt A):73-88.
[13] McClelland A,Hagiwara S,Kantharidis P.Where are we in diabetic nephropathy:microRNAs and biomarkers[J].Curr Opin Nephrol Hypertens,2014,23(1):80-86.
[14] Figueira MF,Monnerat-Cahli G,Medei E,et al.MicroRNAs:potential therapeutic targets in diabetic complications of the cardiovascular and renal systems[J].Acta Physiol(Oxf),2014,211(3):491-500.
[15] Bhatt K,Kato M,Natarajan R,et al.Mini-review:emerging roles of microRNAs in the pathophysiology of renal diseases[J].Am J Physiol Renal Physiol,2016,310(2):F109-F118.

相似文献/References:

[1]张春雷,曾学辉,李忠新,等.尿KIM-1和NGAL在糖尿病肾病早期诊断中的应用[J].现代检验医学杂志,2015,30(01):52.[doi:10.3969/j.issn.1671-7414.2015.01.014]
　ZHANG Chun-lei,ZENG Xue-hui,LI Zhong-xin,et al.Value of Urinary KIM-1 and NGAL in Predicting the Early Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2015,30(03):52.[doi:10.3969/j.issn.1671-7414.2015.01.014]
[2]阿地拉·阿布里孜,王 霞,屈晓威.联合检测视黄醇结合蛋白和膜联蛋白A2水平对糖尿病肾病早期诊断的意义[J].现代检验医学杂志,2016,31(05):118.[doi:10.3969/j.issn.1671-7414.2016.05.033]
　ADILA·Abulizi,WANG Xia,QU Xiao-wei.Significance of Combined Detection of Serum Retinol-Binding Protein and AnnexinA2 in Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2016,31(03):118.[doi:10.3969/j.issn.1671-7414.2016.05.033]
[3]于菲菲,庞白冰,杨 华,等.单纯性2型糖尿病与糖尿病肾病患者尿液中α1-微球蛋白和激肽原1的表达分析[J].现代检验医学杂志,2017,32(05):94.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　YU Fei-fei,PANG Bai-bing,YANG Hua,et al.Expression Analysis of α1-Microglobulin,Kininogen1 in Urine of Simple Type 2 Diabetes and Diabetic Nephropathy Patients[J].Journal of Modern Laboratory Medicine,2017,32(03):94.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[4]杨翠伶.血清miR-150-5p和miR-155-5检测对老年糖尿病肾病的诊断价值[J].现代检验医学杂志,2018,33(05):74.[doi:10.3969/j.issn.1671-7414.2018.05.020]
　YANG Cui-ling.Diagnostic Value of Serum miR-150-5p and miR-155-5 Detection in Elderly Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2018,33(03):74.[doi:10.3969/j.issn.1671-7414.2018.05.020]
[5]谭志敏,张 燕,滕雅娟,等.糖尿病肾病患者血清甲状腺激素水平变化及其与亚临床甲状腺功能减退的相关性[J].现代检验医学杂志,2018,33(06):95.[doi:10.3969/j.issn.1671-7414.2018.06.025]
　TAN Zhi-min,ZHANG Yan,TENG Ya-juan,et al.Correlation between Serum Thyroid Hormone Levels in Patients with Diabetic Kidney Disease and Subclinical Hypothyroidism[J].Journal of Modern Laboratory Medicine,2018,33(03):95.[doi:10.3969/j.issn.1671-7414.2018.06.025]
[6]张求霞a,汪隆海a,昌国庆a,等.尿液6种蛋白与CysC水平检测对糖尿病肾病的诊断价值[J].现代检验医学杂志,2019,34(01):67.[doi:10.3969/j.issn.1671-7414.2019.01.017]
　ZHANG Qiu-xiaa,WANG Long-haia,CHANG Guo-qing a,et al.Clinical Value of Detection of 6 Proteins and Cystatin C in Urine for Early Diagnosis of Diabetic Kidney Disease[J].Journal of Modern Laboratory Medicine,2019,34(03):67.[doi:10.3969/j.issn.1671-7414.2019.01.017]
[7]张曙晴,张骆军,李洪彬,等.血液小而密低密度脂蛋白胆固醇、抗凝血酶Ⅲ水平及血小板参数检测在2型糖尿病肾病中的应用价值研究[J].现代检验医学杂志,2021,36(02):70.[doi:doi:10.3969/j.issn.1671-7414.2021.02.017]
　ZHANG Shu-qing,ZHANG Luo-jun,LI Hong-bin,et al.Study on the Application Value of Detecting Small Dense Low-density Lipoprotein Cholesterol, Antithrombin-Ⅲ Levels and Platelet Parameter in the Patients with Type-2 Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2021,36(03):70.[doi:doi:10.3969/j.issn.1671-7414.2021.02.017]
[8]闫海燕,杨云秀,杨云华,等.老年糖尿病肾病患者血清SP-D水平表达及其基因多态性与并发肺部感染的相关性研究[J].现代检验医学杂志,2021,36(04):21.[doi:10.3969/j.issn.1671-7414.2021.04.005]
　YAN Hai-yan,YANG Yun-xiu,YANG Yun-hua,et al.Research on the Relationship between Serum SP-D Level, Gene Olymorphismand Pulmonary Infection in Elderly Patients with Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2021,36(03):21.[doi:10.3969/j.issn.1671-7414.2021.04.005]
[9]祁桠楠a,胡江伟b,武　亮c,等.血清TLR-3，miR-181b及URBP联合检测在糖尿病肾病诊断及预后判断的价值研究[J].现代检验医学杂志,2022,37(02):37.[doi:10.3969/j.issn.1671-7414.2022.02.008]
　QI Ya-nana,HU Jiang-weib,WU Liangc,et al.Value of Combined Detection of Serum TLR-3, miR-181b and URBP in Diagnosis and Prognosis of Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2022,37(03):37.[doi:10.3969/j.issn.1671-7414.2022.02.008]
[10]周仕群,王　聪,江　强,等.糖尿病肾病患者血清miR-188-5p及miR-379-5p的表达及其临床意义[J].现代检验医学杂志,2022,37(03):91.[doi:10.3969/j.issn.1671-7414.2022.03.019]
　ZHOU Shi-qun,WANG Cong,JIANG Qiang,et al.Expression and Clinical Significance of Serum miR-188-5p and miR-379-5p in Patients with Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2022,37(03):91.[doi:10.3969/j.issn.1671-7414.2022.03.019]

备注/Memo

备注/Memo:
作者简介:吴忠璟(1981-),男,本科,主管检验师,主要从事临床检验诊断学研究,E-mail:A522198993@163.com。
更新日期/Last Update: 2018-04-16